Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer
PROSTATE CANCER
About this trial
This is an interventional treatment trial for PROSTATE CANCER focused on measuring Prostate Cancer, non metastatic prostate cancer, oligometastatic prostate cancer
Eligibility Criteria
Inclusion Criteria:
- Participants must have a diagnosis of castrate resistant prostate cancer.
- Participants must be 18 years old or older.
- Biopsy of tissue from the prostate or enlarged lymph nodes may be required.
- Patients must sign study specific informed consent prior to study entry.
- Men of child-producing potential must be willing to consent to use effective contraception while on treatment and for at least 3 months afterwards.
Exclusion Criteria:
- Participants cannot have prior chemotherapy for prostate cancer.
- Participants cannot have prior radiation therapy to the pelvis.
Sites / Locations
- Hematology Oncology Associates
- Northwestern University, Northwestern Memorial Faculty Foundation
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Chemotherapy alone, no radiation therapy
Chemotherapy with Radiation Therapy
A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel
A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel GROUPS 1 and 2 Whole Pelvis (45 Gy) + Prostate boost (20-25 Gy) in 1.8 Gy fractions, 5 fractions/week. GROUPS 2 Bone metastasis (bone scan index < 1.4%): 30 Gy in 10 fractions or 35 Gy in 12 fractions. GROUPS 1,2 Abdominal Nodes (IF POSITIVE ON CT/MRI SCAN): 45-50 Gy in 1.8 Gy fractions, 5 fractions/week.